Pharmafile Logo
Pharmafocus logo
Advanced Search

Chiesi

Showing 15 posts of 15 posts found.

Chiesi expands La Chaussée-Saint-Victor site to manufacture next-gen inhalers

November 10, 2025
Manufacturing and Production Chiesi, Metered Dose Inhalers, Site Expansion, respiratory diseases

Chiesi, a biopharma group focused on treating respiratory diseases, has inaugurated an expansion of its manufacturing and industrial site in …

News
640px-eye_iris

NICE recommends treatment for rare genetic eye disorder

August 11, 2025
Medical Communications Chiesi, Leber Hereditary Optic Neuropathy, NHS England, National Institute for Health and Care Excellence, Opthalmology, Rare Diseases

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Cheisi’s idebenone (Raxone) within its …

News

Great Place To Work® and Fortune Name Chiesi Group No. 23in 2024 World’s Best Workplaces™ List

November 19, 2024
Chiesi, Corporate, best workplace

Chiesi is the only European pharmaceutical company and the first Italian company ever to be included in the World’s Best …

News
Press release
lungs

Gossamer Bio and Chiesi Group enter into international collaboration to commercialise Seralutinib

May 7, 2024
Research and Development Chiesi, Chronic Diseases, Gossamer Bio, PAH, PH-ILD, collaboration

US-based clinical stage biopharma company Gossamer Bio and Italian research-focused biopharma group Chiesi Farmaceutici have entered into an international agreement …

News
online_feature_image

New Year, new goals

February 8, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CRUK, Cancer Research UK, Chiesi, EMA, FDA, Genetic Alliance, pharma

With the New Year begun in earnest, Pharmafocus speaks to a range of players in pharma and the life sciences …

Feature
european_commission_web

EMA committee recommends seven therapies from Roche, GSK, MSD and more

January 29, 2018
Sales and Marketing Biocon, Chiesi, Chugai, GSK, GlaxoSmithKline, MSD, Mylan, Roche, Sanofi, pharma

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has voiced its recommendation of a raft of …

News
hold_heart

Chiesi set to acquire Medicine Co cardiovascular assets, say reports

May 9, 2016
Sales and Marketing Chiesi, assets, cardiovascular, medicine co

Italian pharmaceutical company Chiesi are set to expand their global footprint as it nears an agreement to acquire Medicines Co’s …

News
Chiesi image

Chiesi rapped for ABPI code breach

May 7, 2015
Medical Communications, Sales and Marketing ABPI, Chiesi, PMCPA

Chiesi made its sales reps go through a ‘tick-box’ compliance training exercise to get the pharma industry regulator ‘off its …

News
Chiesi image

Chiesi reprimanded again over Fostair drug

March 3, 2015
Manufacturing and Production, Medical Communications, Sales and Marketing ABPI, Chiesi, PMCPA, code, formoterol/beclometason, fostair

Chiesi has been reprimanded after it breached the ABPI’s Code of Practice for its promotion of asthma inhaler Fostair. The …

News
Chiesi image

Chiesi’s stem cell therapy approved in Europe

February 23, 2015
Research and Development, Sales and Marketing Chiesi, EC, Europe, Holoclar, Holostem Advanced Therapies, LSCD, stem cell

Chiesi’s Holoclar has become the first stem cell therapy to get the green light in Europe, gaining conditional approval from …

News

Chiesi gets first-ever European stem cell nod

December 19, 2014
Sales and Marketing Chiese, Chiesi, EMA, Holoclar, LSCD, MHRA, Stem cells, orexigen

Chiesi has received the first approval for an advanced therapy medicinal product containing stem cells for use in Europe. The …

News
Chiesi image

Chiesi publicly reprimanded

December 13, 2013
Sales and Marketing ABPI, Chiesi, PMCPA, fostair

Chiesi has had the book thrown at it by the PMCPA and faces the shame of a public reprimand – …

News
Chiesi image

Chiesi snaps up Zymenex

August 29, 2013
Sales and Marketing Chiesi, lamazym, rare diseases, zymenex

Chiesi Group is to acquire biopharma company Zymenex Holdings, allowing the Italian firm to enter the rare disease arena for …

News

PMCPA reprimands Chiesi for multiple breaches

June 18, 2012
Sales and Marketing COPD, Chiesi, GSK, PMCPA, code

Chiesi has been publicly reprimanded by the PMCPA part for promoting its asthma drug Fostair off-label. The embarrassing slapdown from …

News

Chiesi breaks ground on new R&D headquarters in Palma

July 13, 2009
Research and Development Chiesi, Europe, Italy

Construction of Chiesi's new 70 million euro centre for research and development has begun in Parma, Italy. The Italian company …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026